Search
MBO7133
go.drugbank.com/drugs/DB04999ExperimentalMB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer.
Dental Mesenchymal Pulp Stem Cells
go.drugbank.com/drugs/DB15737InvestigationalDPSCs have multiple properties, and express surface antigens like CD90, CD29, and CD105 but not CD14 or CD45.
Phenserine
go.drugbank.com/drugs/DB04892InvestigationalPhenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia.
ETC-588
go.drugbank.com/drugs/DB05456ExperimentalIt is believed that the removal of cholesterol by ETC-588 through this pathway may result in the reversal of atherosclerosis.
OT-551
go.drugbank.com/drugs/DB05650InvestigationalAge-related macular Degeneration (AMD), and preclinical research results indicate additional uses for OT-551, including treatment of early stage and advanced dry age-related macular degeneration (AMD) by
Inactivated SARS-Cov-2 Vaccine
go.drugbank.com/drugs/DB15862InvestigationalDeveloped by Sinopharm's Wuhan Institute of Biological Products co., this vaccine consists of the WIV04 strain of SARS-CoV-2.
MVA-BN-brachyury-TRICOM vaccine
go.drugbank.com/drugs/DB17424Investigational[L44513] MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of the fowlpox virus(FPV)âBrachyury booster vaccine.
TMC-310911
go.drugbank.com/drugs/DB15623Investigational[L12045,A191643] TMC-310911 is currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19 caused by SARS-CoV-2.[L12012]
Metamizole
go.drugbank.com/drugs/DB04817ApprovedInvestigationalWithdrawnMetamizole (dipyrone) is a pyrazolone derivative that belongs to the group of nonacid nonopioids. It is considered a potent analgesic and antipyretic with favourable gastrointestinal tolerability. Metamizole was formerly marketed in the ...
Ertiprotafib
go.drugbank.com/drugs/DB06521ExperimentalErtiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes. In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improv...